Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with ...

Sobi to advance Gamifant in interferon-gamma-driven sepsis based on EMBRACE topline data: Stockholm Friday, January 9, 2026, 11:00 Hrs [IST] Sobi, a global biopharma company, anno ...

Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven ...

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune ...

Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system ...

MS is currently treated with 'disease-modifying' medicines (e.g. interferon beta, glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate). These medicines can ...

This review synthesizes clinical, genetic, and mechanistic evidence showing that suPAR and related uPAR fragments are ...

The Phase 2a trial enrolled 35 IPF patients randomized in a 2:1 ratio to receive either GRI-0621 or placebo once daily for 12 weeks. A sub-study examined immune cells in bronchoalveolar lavage fluid ...

Encephalitis is an inflammation of the brain that can be caused by infections or autoimmune reactions. Even when patients survive the acute phase, many are left with long-lasting neurological problems ...

Explore how aggressive breast cancer evades immune defences and discover potential treatment strategies with our latest ...

BATF2 is a new type of tumor suppressor that can be epigenetically silenced by high levels of glutamine in the tumor microenvironment Glutamine silences BATF2 and leads to a weakened immune response ...